Join us in-person for Arrowhead Pharmaceuticals’ R&D Day discussing the progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025.

The R&D Day will feature presentations by three key opinion leaders: Ira Goldberg, M.D. (NYU Langone Medical Center), who will discuss the unmet medical need in treating patients with hypertriglyceridemia and mixed dyslipidemia; Matthias Salathe, M.D. (University of Kansas Medical Center), who will discuss the muco-obstructive and inflammatory pulmonary disease landscape; and, Michael Benatar, M.D., Ph.D. (University of Miami Miller School of Medicine), who will discuss ALS caused by SOD1 mutations. The event will also feature presentations by the Arrowhead team, who will provide updates on the company’s ongoing cardiometabolic, pulmonary, CNS, and other liver targeted programs.

A live question and answer session will follow the formal presentations.